Logo image of FRX.CA

FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Fundamental Analysis

TSX:FRX - Toronto Stock Exchange - CA31447P1009 - Common Stock - Currency: CAD

9.5  +0.63 (+7.1%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to FRX. FRX was compared to 25 industry peers in the Biotechnology industry. FRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FRX is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year FRX has reported negative net income.
FRX had a positive operating cash flow in the past year.
In the past 5 years FRX always reported negative net income.
In the past 5 years FRX always reported negative operating cash flow.
FRX.CA Yearly Net Income VS EBIT VS OCF VS FCFFRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

FRX's Return On Assets of -1.92% is fine compared to the rest of the industry. FRX outperforms 80.00% of its industry peers.
FRX has a Return On Invested Capital of 2.35%. This is amongst the best in the industry. FRX outperforms 85.00% of its industry peers.
Industry RankSector Rank
ROA -1.92%
ROE N/A
ROIC 2.35%
ROA(3y)-75.05%
ROA(5y)-74.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FRX.CA Yearly ROA, ROE, ROICFRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800

1.3 Margins

Looking at the Operating Margin, with a value of 3.41%, FRX belongs to the top of the industry, outperforming 85.00% of the companies in the same industry.
FRX's Gross Margin of 93.52% is amongst the best of the industry. FRX outperforms 100.00% of its industry peers.
Industry RankSector Rank
OM 3.41%
PM (TTM) N/A
GM 93.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRX.CA Yearly Profit, Operating, Gross MarginsFRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, FRX has more shares outstanding
Compared to 5 years ago, FRX has more shares outstanding
FRX has a worse debt/assets ratio than last year.
FRX.CA Yearly Shares OutstandingFRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
FRX.CA Yearly Total Debt VS Total AssetsFRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -1.49, we must say that FRX is in the distress zone and has some risk of bankruptcy.
FRX's Altman-Z score of -1.49 is fine compared to the rest of the industry. FRX outperforms 70.00% of its industry peers.
FRX has a debt to FCF ratio of 1.27. This is a very positive value and a sign of high solvency as it would only need 1.27 years to pay back of all of its debts.
The Debt to FCF ratio of FRX (1.27) is better than 95.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.27
Altman-Z -1.49
ROIC/WACCN/A
WACCN/A
FRX.CA Yearly LT Debt VS Equity VS FCFFRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 7.80 indicates that FRX has no problem at all paying its short term obligations.
FRX has a Current ratio of 7.80. This is amongst the best in the industry. FRX outperforms 95.00% of its industry peers.
A Quick Ratio of 7.64 indicates that FRX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 7.64, FRX belongs to the best of the industry, outperforming 95.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.8
Quick Ratio 7.64
FRX.CA Yearly Current Assets VS Current LiabilitesFRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

FRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.81%, which is quite impressive.
Looking at the last year, FRX shows a very strong growth in Revenue. The Revenue has grown by 277.57%.
The Revenue has been growing by 400.02% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)94.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)277.57%
Revenue growth 3Y400.02%
Revenue growth 5YN/A
Sales Q2Q%12.77%

3.2 Future

FRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.56% yearly.
FRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.91% yearly.
EPS Next Y137.46%
EPS Next 2Y51.14%
EPS Next 3Y63.82%
EPS Next 5Y40.56%
Revenue Next Year179.16%
Revenue Next 2Y72.58%
Revenue Next 3Y69.4%
Revenue Next 5Y43.91%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
FRX.CA Yearly Revenue VS EstimatesFRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M
FRX.CA Yearly EPS VS EstimatesFRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

FRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
FRX is valuated quite expensively with a Price/Forward Earnings ratio of 38.59.
90.00% of the companies in the same industry are more expensive than FRX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of FRX to the average of the S&P500 Index (22.68), we can say FRX is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 38.59
FRX.CA Price Earnings VS Forward Price EarningsFRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

100.00% of the companies in the same industry are more expensive than FRX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.81
EV/EBITDA N/A
FRX.CA Per share dataFRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

FRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FRX's earnings are expected to grow with 63.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.14%
EPS Next 3Y63.82%

More info and screens

0

5. Dividend

5.1 Amount

FRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FENNEC PHARMACEUTICALS INC

TSX:FRX (2/21/2025, 7:00:00 PM)

9.5

+0.63 (+7.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-17 2025-03-17/amc
Inst Owners58.82%
Inst Owner ChangeN/A
Ins Owners1.74%
Ins Owner ChangeN/A
Market Cap261.54M
Analysts85.45
Price Target20.1 (111.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-334.04%
Min EPS beat(2)-539.32%
Max EPS beat(2)-128.76%
EPS beat(4)1
Avg EPS beat(4)-248.1%
Min EPS beat(4)-539.32%
Max EPS beat(4)75.87%
EPS beat(8)3
Avg EPS beat(8)-123.11%
EPS beat(12)4
Avg EPS beat(12)-100.84%
EPS beat(16)7
Avg EPS beat(16)-73.96%
Revenue beat(2)0
Avg Revenue beat(2)-29.72%
Min Revenue beat(2)-35.56%
Max Revenue beat(2)-23.88%
Revenue beat(4)2
Avg Revenue beat(4)-4.39%
Min Revenue beat(4)-35.56%
Max Revenue beat(4)31.8%
Revenue beat(8)4
Avg Revenue beat(8)9.38%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.27%
PT rev (3m)11.73%
EPS NQ rev (1m)4884.98%
EPS NQ rev (3m)4884.98%
EPS NY rev (1m)540%
EPS NY rev (3m)51.86%
Revenue NQ rev (1m)120.38%
Revenue NQ rev (3m)120.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)24.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 38.59
P/S 3.73
P/FCF 7.81
P/OCF 7.81
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)0.25
Fwd EY2.59%
FCF(TTM)1.22
FCFY12.8%
OCF(TTM)1.22
OCFY12.8%
SpS2.54
BVpS-0.27
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.92%
ROE N/A
ROCE 3.27%
ROIC 2.35%
ROICexc 10.86%
ROICexgc 10.86%
OM 3.41%
PM (TTM) N/A
GM 93.52%
FCFM 47.81%
ROA(3y)-75.05%
ROA(5y)-74.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.27
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.8
Quick Ratio 7.64
Altman-Z -1.49
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y137.46%
EPS Next 2Y51.14%
EPS Next 3Y63.82%
EPS Next 5Y40.56%
Revenue 1Y (TTM)277.57%
Revenue growth 3Y400.02%
Revenue growth 5YN/A
Sales Q2Q%12.77%
Revenue Next Year179.16%
Revenue Next 2Y72.58%
Revenue Next 3Y69.4%
Revenue Next 5Y43.91%
EBIT growth 1Y109.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year163.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y262.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y262.7%
OCF growth 3YN/A
OCF growth 5YN/A